Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Class Action Details - A class action lawsuit has been filed against Cytokinetics, alleging that the company made false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten [4] - The lawsuit claims that Cytokinetics misrepresented the expected FDA approval timeline, indicating approval in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokinet ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to dis ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, ...

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025, which is in violation of federal securities laws [1][3]. Summary by Sections Lawsuit Details - Investors have until November 17, 2025, to file lead plaintiff applications in the lawsuit against Cytokinetics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. Company Disclosures - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting to review its New Drug Application for the aficamten product [4]. - On May 6, 2025, the company revealed it had multiple pre-NDA meetings with the FDA regarding safety monitoring and risk mitigation but opted to submit the NDA without a Risk Evaluation and Mitigation Strategy [4]. Stock Price Impact - Following the disclosures, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5]. Law Firm Background - Kahn Swick & Foti, LLC is a prominent securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including institutional and retail investors, seeking recoveries for investment losses due to corporate fraud [5].

Core Viewpoint - A class action has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Allegations and Legal Action - The class action is on behalf of individuals and entities that purchased Cytokinetics securities between December 27, 2023, and May 6, 2025 [1]. - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission and approval process for aficamten, specifically regarding the expected approval timeline from the U.S. Food and Drug Administration (FDA) [2]. - Defendants claimed that approval was expected in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [2]. Group 2: Participation and Representation - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, to represent other class members in the litigation [3]. - Shareholders can choose not to participate in the case and still remain eligible for recovery as absent class members [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. DEADLINE: November 17, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [4][6][8]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][4]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [4]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, specifically regarding the expected FDA approval in the second half of 2025 [6]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which misled investors about the regulatory timeline [7]. Group 3: Investor Impact - As a result of the misleading statements, investors purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was disclosed [8]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [9].